Legend Biotech
LEGN
207 hedge funds and large institutions have $2.91B invested in Legend Biotech in 2025 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 76 increasing their positions, 80 reducing their positions, and 31 closing their positions.
5% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 80
10% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 31
1% less funds holding
Funds holding: 210 → 207 (-3)
3.36% less ownership
Funds ownership: 26.94% → 23.58% (-3.4%)
10% less capital invested
Capital invested by funds: $3.23B → $2.91B (-$324M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
44% less call options, than puts
Call options by funds: $9.37M | Put options by funds: $16.8M
Top Buyers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$43.2M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$35.5M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$21.9M |
| 4 |
Millennium Management
New York
|
+$21.6M |
| 5 |
Morgan Stanley
New York
|
+$21.5M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$244M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$98.6M |
| 3 |
Goldman Sachs
New York
|
-$55.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$32.2M |
| 5 |
JP Morgan Chase
New York
|
-$24.4M |
LEGN Hedge Fund Activity: Q1 2025 in Review
207 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2025, worth a combined $2.91B — down 10% from $3.23B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of LEGN and 28 opened new positions — a net loss of 3 holders — while 80 trimmed existing stakes and 76 added.
The largest buyer was Westfield Capital Management, adding an estimated $43.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $244M sold.
- 207 institutional investors held Legend Biotech (LEGN) as of Q1 2025, down from 210 in Q4 2024.
- Funds reported $2.91B of Legend Biotech stock for Q1 2025, down 10% quarter-over-quarter.
- 28 funds opened new Legend Biotech positions in Q1 2025 and 31 closed out, a net change of -3 holders.
- The largest Legend Biotech buyer in Q1 2025 was Westfield Capital Management, an estimated $43.2M added.
- The largest Legend Biotech seller in Q1 2025 was RA Capital Management, an estimated $244M sold.
Based on aggregated 13F filings for Q1 2025.